Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
83 hedge funds and large institutions have $78.9M invested in Regulus Therapeutics in 2016 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 49 increasing their positions, 14 reducing their positions, and 28 closing their positions.
566% more call options, than puts
Call options by funds: $4.7M | Put options by funds: $706K
250% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 14
18% less funds holding
Funds holding: 101 → 83 (-18)
61% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 28
67% less capital invested
Capital invested by funds: $236M → $78.9M (-$157M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$5.1M |
| 2 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$4.99M |
| 3 |
SDIC
South Dakota Investment Council
Sioux Falls,
South Dakota
|
+$4.61M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.53M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$24.5M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$14.9M |
| 3 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$14.1M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$7.24M |
| 5 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$5.47M |
RGLS Hedge Fund Activity: Q2 2016 in Review
83 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q2 2016, worth a combined $78.9M — down 67% from $236M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of RGLS and 11 opened new positions — a net loss of 17 holders — while 14 trimmed existing stakes and 49 added.
The largest buyer was Wellington Management Group, adding an estimated $5.1M. The largest seller was Capital World Investors, exiting entirely with an estimated $24.5M sold.
- 83 institutional investors held Regulus Therapeutics (RGLS) as of Q2 2016, down from 101 in Q1 2016.
- Funds reported $78.9M of Regulus Therapeutics stock for Q2 2016, down 67% quarter-over-quarter.
- 11 funds opened new Regulus Therapeutics positions in Q2 2016 and 28 closed out, a net change of -17 holders.
- The largest Regulus Therapeutics buyer in Q2 2016 was Wellington Management Group, an estimated $5.1M added.
- The largest Regulus Therapeutics seller in Q2 2016 was Capital World Investors, an estimated $24.5M sold.
Based on aggregated 13F filings for Q2 2016.